ARGX vs REGN
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
ARGX · argenx SE$927.21 ▲ 3.63%
REGN · Regeneron Pharmaceuticals$904.35 ▲ 0.16%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- ARGX +6.6%
- REGN +38.8%
Head to head
| Metric | ARGX | REGN |
|---|---|---|
| Price | $927.21 | $904.35 |
| Change today | ▲ 3.63% | ▲ 0.16% |
| Market cap | $58.31B | $93.55B |
| Return, 3 months | +7.1% | +12.0% |
| Return, year to date | +10.3% | +17.6% |
| Return, 1 year | +8.5% | +38.2% |
| P/E (TTM) | 32.1 | 20.0 |
| P/B | 6.9 | 2.8 |
| P/E percentile vs own 5y | 67th | 81st |
| Dividend yield | – | 0.41% |
| Revenue growth (YoY, latest qtr) | +52.7% | +36.3% |
| Net profit growth (YoY) | +47.1% | +33.5% |
| Gross margin | 90.0% | 85.8% |
| Operating margin | 29.9% | 30.4% |
| Net margin | 32.2% | 28.5% |
| Return on equity | – | 14.9% |
| Analyst target vs. price | +25.8% | +6.1% |
| Analyst buy share | 95% | 70% |
| RSI (14) | 56 | 63 |
| 30-day volatility | 50.8% | 48.7% |
| Max drawdown, 1 year | -28.6% | -25.9% |
| Trend read | Strong uptrend | Strong uptrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- REGN is the largest of the group by market value.
- REGN has returned the most over the past year.
- REGN carries the lowest trailing P/E.
- ARGX is growing revenue fastest.
- ARGX keeps the most profit per dollar of sales.
- REGN has been the calmest stock over the last 30 days.